Navigation Links
For Patients on Statins, Study Finds Filling 90 Day Supply Prescriptions through Mail Service Compared to Retail Pharmacy is Associated with Less Waste
Date:4/27/2011

ST. PAUL, Minn., April 27, 2011 /PRNewswire/ -- A new study shows 90-day statin drug claims filled through a mail service pharmacy are associated with less waste than a 90-day supply from a retail pharmacy. The findings of the study by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, will be presented at the Academy of Managed Care Pharmacy's 23rd Annual Meeting and Showcase, taking place in Minneapolis, Minn. April 27-29.

Waste occurs when patients stop taking their medication, as a result of a dosage or drug switch, before the entire supply is used. Increasingly, patients with chronic conditions are moving to 90-day prescriptions, and previous studies have shown those receiving a 90-day prescription adhere better to their medications compared to those with a 30-day prescription.

"As an increasing number of patients move to 90-day prescriptions, this study shows we have an opportunity to reduce medication waste as a result of a dosage or drug switch if patients fill their prescription through mail service," said Patrick Gleason, PharmD, director of Clinical Outcomes Assessment, Prime.

For the study, researchers reviewed the claims of 51,261 Blue Cross and Blue Shield (BCBS) members who received statin prescriptions to identify those with overlapping claims. Researchers reviewed prescriptions filled from the second quarter of 2009 to the second quarter of 2010, via a retail pharmacy 30-day supply, a retail pharmacy 90-day supply and a mail service 90-day supply.

The results of the study show 3,996 of the 51,261 members (7.8 percent) with a statin claim had at least one day of waste, and the average days of waste was 24. Those receiving a 90-day supply via retail pharmacy had significantly higher waste (p<0.001) than those receiving their prescription through 30-day retail supply or 90-day mail service. Among those who received their medication through 90-day retail supply, those who were unable to use their entire prescription averaged 38.7 days of waste, compared to 35.9 days of waste among those with a 90-day mail service prescription who did not use all of their prescription. In comparison, patients filling a statin prescription via a retail pharmacy 30-day supply who did not use all of their medication averaged 12.4 days of waste.

"Physicians that are prescribing long-term statin medications to patients already established on a drug for chronic cardiovascular disease should consider having their patient fill their prescription via mail service to help reduce medication waste," said Gleason. "For many patients, not only are 90-day mail service supplies associated with reduced waste, they save consumers money and time."

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to nearly 17 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 12 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. Many Heart Attack Patients Dont Get Best Emergency Treatment
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)...  West Pharmaceutical Services, Inc. (NYSE: WST ... 2017 and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, ... Net sales at constant currency (organic) grew by 3.9%. ... compared to $0.60 in the prior-year quarter. Second-quarter 2017 ...
(Date:7/26/2017)... Aesthetics, a leading medical aesthetic clinic in Singapore ... skin conditions from the inside. The natural process of ... skin becomes more transparent due to the thinning of the epidermis. Over ... the sun contributes to aging skin, causing age spots and other ... ...
(Date:7/26/2017)... 26, 2017 The Galien Foundation announced ... USA Award Nominees. Counted among the global ... recognizes outstanding biomedical and technology product achievement that improves the ... qualify, each candidate must be U.S. Food and Drug Administration ... demonstrate tremendous potential to impact human health. Sales data are ...
Breaking Medicine Technology:
(Date:7/27/2017)... Plano, TX (PRWEB) , ... July 27, 2017 ... ... technology and outsourced services, announces the internal promotion of Elrene Clinkscales to Vice ... Operations – Claims & Remittance Management, reporting to Derek Morkel, chief executive officer ...
(Date:7/27/2017)... ... 2017 , ... Team Novo Nordisk, the world’s first all-diabetes professional cycling team, ... a stagiaire for the remainder of the 2017 season. One of our best development ... Tour of Utah. , “Every season we are excited to move an athlete from ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: Ashley D. Beall, ... in drug therapy for patients living with relapsing and primary multiple sclerosis that ... cell targeted therapy that has been proven to significantly reduce signs of disease ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are dentists and we thought there ... Jose, Calif., “so we invented the MAGNETIC/ LOCK BRACKETS.” , The patent-pending MAGNETIC/ LOCK ... In doing so, it offers an effective alternative to traditional braces. As a result, ...
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be ... for patients to schedule an appointment online in real time,” said Keith English, LocalMed ... Smiles provider directory will bring more Six Month Smiles patients to their providers.” , ...
Breaking Medicine News(10 mins):